Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9
Open Access
- 30 September 2001
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 4 (3), 201-210
- https://doi.org/10.1006/mthe.2001.0441
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarizationNature Medicine, 1999
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vectorNature Medicine, 1999
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virusProceedings of the National Academy of Sciences, 1997
- Recombinant adeno-associated virus for muscle directed gene therapyNature Medicine, 1997
- Factor IX Inhibitors and Anaphylaxis in Hemophilia BJournal of Pediatric Hematology/Oncology, 1997
- 1 The molecular basis of haemophilia A and BBailliere's Clinical Haematology, 1996
- Factor IX:Molecular structure, epitopes, and mutations associated with inhibitor formationPublished by Springer Nature ,1995